Proyl isomerase Pin1 facilitates ubiquitin-mediated degradation of cyclin-dependent kinase 10 to induce tamoxifen resistance in breast cancer cells

HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib

(2010) Giorgio Valabrega et al.   BREAST CANCER RESEARCH AND TREATMENT

The Prolyl Isomerase Pin1 Induces LC-3 Expression and Mediates Tamoxifen Resistance in Breast Cancer

(2010) Gwang Mo Namgoong et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Ras/Raf-1/MAPK Pathway Mediates Response to Tamoxifen but not Chemotherapy in Breast Cancer Patients

(2009) L. M. McGlynn et al.   CLINICAL CANCER RESEARCH

Identification of CDK10 as an Important Determinant of Resistance to Endocrine Therapy for Breast Cancer

(2008) Elizabeth Iorns et al.   CANCER CELL

Tamoxifen Resistance in Breast Tumors Is Driven by Growth Factor Receptor Signaling with Repression of Classic Estrogen Receptor Genomic Function

(2008) S. Massarweh et al.   CANCER RESEARCH

Phosphorylation-Specific Prolyl Isomerase Pin1 as a new Diagnostic and Therapeutic Target for Cancer

(2008) Greg Finn et al.   CURRENT CANCER DRUG TARGETS

Cdk2 and Pin1 negatively regulate the transcriptional corepressor SMRT

(2008) Kristopher J. Stanya et al.   JOURNAL OF CELL BIOLOGY